丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

novartis healthcare a/s - ondansetron - injektionsvæske, opløsning - 2 mg/ml

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - amiodaronhydrochlorid - koncentrat til injektions-/infusionsvæske, opløsning - 50 mg/ml

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

esteve pharmaceuticals s.a.s. - streptozocin - pulver til koncentrat til infusionsvæske, opløsning - 1 g

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

macure pharma aps - carmustin - pulver og solvens til koncentrat til infusionsvæske, opløsning - 100 mg

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - carvedilol - tabletter - 25 mg

欧盟 - 丹麦文 - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - stråling skader - detoxifying agents for antineoplastic treatment - lysakare er indiceret til reduktion af nyre-stråling i løbet af peptid-receptor radionuklid terapi (prrt) med lutetium (177lu) oxodotreotide i voksne.

欧盟 - 丹麦文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - streptozocin - pulver til koncentrat til infusionsvæske, opløsning - 1 g

欧盟 - 丹麦文 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andre præparater antianemic - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

欧盟 - 丹麦文 - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - bryst neoplasmer - antineoplastiske midler - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.